This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kalra, P. R Search for Related Content Social Bookmarking                         What's this?

Has abciximab's ship come in?

Results from the ADMIRAL investigators and diabetic substudy

National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK, p.kalra{at}ic.ac.uk

The ADMIRAL (Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up) study is a multicentre, double-blind trial in 300 patients presenting with myocardial infarction. They were randomised to treatment with abciximab or placebo, followed by stenting. Abciximab treatment in diabetic and non-diabetic patients improved outcomes at 30 days and 6 months, with these improvements being related to a higher frequency of normal coronary blood flow at 24 hours and 6 months after intervention.

Key Words: myocardial infarction • primary angioplasty • anti-platelet agent.

References

• Simes RJ, Topol EJ, Holmes DR Jr et al. Link between the angiographic substudy and mortality outcomes in a large randomised trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-1 Investigators. Circulation 1995;91:1923-8.[Abstract/Free Full Text]
• Grines CL, Cox DA, Stone GW et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341:1949-56.[Abstract/Free Full Text]
• Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41.[Abstract/Free Full Text]
• Montalescot G., Barragan P., Wittenberg O. et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.[Abstract/Free Full Text]
• Montalescot G., Barragan P., Wittemberg O. et al. Abciximab reduces clinical restenosis in diabetic patients undergoing primary stenting for acute myocardial infarction (The ADMIRAL study). Circulation 2001;104 (suppl):II-386 (Abstract).
• Bertrand ME, Rupprecht HJ, Urban P. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.[Abstract/Free Full Text]
• Marso SP, Lincoff AM, Ellis SG et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999;100:2477-84.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1, 30-31 (2002)
DOI: 10.1177/14746514020020011501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kalra, P. R Search for Related Content Social Bookmarking                         What's this?